Common Stock, $0.0001 par value per share

Invivyd, Inc.

209 Church Street, New Haven, CT, 06510

Item 2 of the Schedule 13D is hereby amended and restated as follows: (a) The Schedule 13D is being filed by Adimab, LLC (the "Reporting Person"), a Delaware limited liability company. Information with respect to the directors and executive officers of the Reporting Person (collectively, the "Related Persons") is included in Appendix A to this Schedule 13D.

(b) The business address of the Reporting Person is 7 Lucent Drive, Lebanon, NH 03766.

(c) The Reporting Person's principal business is to provide therapeutic antibody discovery and enginerring technologies.

(e) None

(f) The Reporting person is a Delaware limited liability company.

Item 5 of the Schedule 13D is hereby amended and restated as follows: (a) Amount beneficially owned: 21,687,906; Percent of Class: 8.8%. The above percentage is based on 233,122,834 shares of Common Stock outstanding as of October 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

(b) The Reporting Person has sole voting and sole dispositive power with respect to all of the shares of Common Stock that it beneficially owns.

On November 17, 2025, the Reporting Person sold 1,233,416 shares of Common Stock at a weighted average price of $3.0026 per share in a series of open market transactions. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.045 per share. The Reporting Person undertakes to provide to the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

None

Not applicable